The drugs, sutezolid and delpazolid, have demonstrated strong antimicrobial activity and a notably better safety profile ...

The CEO of GH Research, Dr. Velichka Valcheva, pointed out that the response addressed the FDA’s requests with comprehensive ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

Farber, with the creation of a new cancer hospital, is moving forward after the completion of the regulatory process.

How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical ...

Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

Discover what clinical trials are, why they're vital for new treatments, and how you can participate in life-changing medical research.

Boehringer Ingelheim today announces the start of the THULITE Phase II clinical study (NCT06962839). It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral ...

Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has recommended ...

The initial implementation phase of myUABResearch, the university’s new electronic research administration system, is on ...